The US Food and Drug Administration issued 510(k) clearance and CLIA waiver for Diasorin’s four‑plex molecular assay on the Liaison Nes platform, enabling point‑of‑care detection of influenza A/B, RSV and SARS‑CoV‑2. Diasorin said the Liaison Nes, developed with a major US pharmacy chain, delivers results in about 15 minutes via a three‑step workflow and is positioned to expand rapid molecular testing outside centralized labs. Diasorin framed the clearance as its entry into the molecular POC market and said additional infectious‑disease assays are planned for the platform. The CLIA waiver removes the requirement for specialized laboratory personnel, increasing the potential deployment footprint in retail clinics and pharmacies. Regulatory clearance of rapid molecular platforms continues to shift diagnostic capacity toward decentralized settings, which could affect testing strategies for seasonal respiratory viruses and future outbreak responses.